Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 6/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.40 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16730886 | 1.00 | CYP11B2 (0.46) | CYP11B2CYP11B1IDO1CYP3A4CYP2D6 | |
| SCHEMBL18128796 | 0.88 | CYP11B2 (0.41) | CYP11B2CYP11B1IDO1CYP3A4CYP2D6 | |
| SCHEMBL16719057 | 0.88 | CYP11B2 (0.41) | CYP11B2CYP11B1IDO1CYP3A4CYP2D6 | |
| SCHEMBL20170510 | 0.87 | CYP11B2 (0.42) | CYP11B2CYP11B1IDO1CYP3A4CYP2D6 | |
| SCHEMBL20162457 | 0.86 | IDO1 (0.42) | CYP11B2CYP11B1IDO1CYP3A4CYP2D6 | |
| SCHEMBL16730887 | 0.86 | IDO1 (0.42) | CYP11B2CYP11B1IDO1CYP3A4CYP2D6 | |
| SCHEMBL20170508 | 0.85 | IDO1 (0.43) | CYP11B2CYP11B1IDO1CYP3A4CYP2D6 | |
| SCHEMBL18128804 | 0.85 | FKBP1A (0.44) | CYP11B2IDO1CYP3A4CYP2D6CYP2B6 | |
| SCHEMBL16719008 | 0.85 | FKBP1A (0.44) | CYP11B2IDO1CYP3A4CYP2D6CYP2B6 | |
| SCHEMBL16730872 | 0.84 | IDO1 (0.44) | CYP11B2IDO1CYP3A4CYP2D6CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3068391-B1 | ARYL LINKED IMIDAZOLE AND TRIAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG | MERCK SHARP & DOHME (US) | 2018-05-23 | — | — | EP | disclosed |
| US-9975888-B2 | Aryl linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug | MERCK SHARP & DOHME CORP. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20160297809-A1 | ARYL LINKED IMIDAZOLE AND TRIAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG | MERCK SHARP & DOHME CORP. (US) | 2016-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297809-A1 | ARYL LINKED IMIDAZOLE AND TRIAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG | CYP3A43, CYP3A5, CYP3A4 | CYP11B2 30/4885CYP11B1 34/4885IDO1 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.